PARP1 and neoplasm: Preclinical studies in SSTR2-expressing neuroendocrine cell lines or tumor slices demonstrated that poly(ADP-ribose) polymerase-1 (PARP) inhibitors talazoparib, olaparib, and 1,5-dihydroxyisochinolin in combination with [177Lu]Lu-DOTA-TATE increased the number of double-strand breaks and reduced cell/tumor growth further than either treatment alone 124, 125.